Industries > Pharma > The Companion Diagnostics (CDx) Market Forecast 2018-2028

The Companion Diagnostics (CDx) Market Forecast 2018-2028

Leading Companies, Trends and Developments in the Growing Theranostics Market

PUBLISHED: 10 April 2018
PAGES: 183
PRODUCT CODE: PHA0300

Clear
WOOCS 2.2.1
DOWNLOAD SAMPLE

What can be expected from the Companion Diagnostics market? Which areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2028, assessing data, trends, opportunities and prospects there.
 
Our 183-page report provides 127 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across the whole companion diagnostics market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.

Forecasts from 2018-2028 and other analyses show you commercial prospects
Besides revenue forecasting to 2028, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter’s Five Forces analysis) and commercial developments.

The report also includes will find revenue forecasts to 2028 for the following submarkets in the companion diagnostics market:
• Theranostics
• Other Companion Diagnostics

Additionally, this report includes a forecast to 2026 for the global in vitro diagnostics market.

The report also includes will find revenue forecasts to 2028 for the following national and regional markets for companion diagnostics:
• US
• Germany
• France
• Italy
• Spain
• UK
• Japan
• China
• India
• Russia
• Brazil
• South Korea

The Companion Diagnostics (CDx) Market Forecast 2018-2028

The report provides detailed profiles of key companies operating within the companion diagnostics market:
• F. Hoffmann-La Roche Ltd
• Qiagen N.V.
• Abbott Laboratories
• Agilent Technologies
• Myriad Genetics
• bioMerieux
• Thermo Fisher Scientific

Leading companies and potential for market growth
Overall revenue for the Companion Diagnostics market will reach $14.60n in 2023, our work forecasts. We predict strong revenue growth through to 2028. Advances in cellular and tissue research, an improving regulatory landscape, strong support from governments in multiple regions and the launch of several new therapies in areas of unmet clinical need will drive sales to 2028.

Our work analyses the key companies in the market. See visiongain’s analysis of 7 leading companies, including these:
• F. Hoffmann-La Roche Ltd
• Qiagen N.V.
• Abbott Laboratories
• Agilent Technologies
• Myriad Genetics
• bioMerieux
• Thermo Fisher Scientific

A company profile gives you the following information where available:
• Discussion of a company’s activities and outlook
• Historic revenue, analysis and discussion of company performance over the past 5 years
• Analysis of major products currently on the market
• Acquisitions and strategic partnerships

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect the companion diagnostics industry?
Our new report discusses issues and events affecting the companion diagnostics market. You will find discussions, including qualitative analyses:
• Highly diverse market needing strong knowledge of key therapeutic indications
• Changing regulatory landscape challenging new entrants and major market players alike
• Emerging therapies with the potential to reshape the market

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Companion Diagnostics: Market Forecast 2018-2028 report helps you
In summary, our 183-page report gives you the following knowledge:
• Revenue forecasts to 2028 for the Companion Diagnostics market – discover the industry’s prospects, finding promising places for investments and revenues
• Revenue forecasts to 2028 for each major submarket – discover prospects for leading companion diagnostics products in the following areas: theranostics and other companion diagnostics.
• Revenue forecasts to 2028 for twelve leading national markets – US, Germany, France, Italy, Spain, UK, Japan, China, India, Russia, Brazil and South Korea
• Assessment of 7 leading companies – analysis of products, revenue, mergers & acquisitions, sales by region and products
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain’s study is for everybody needing commercial analyses for the companion diagnostics market and leading companies. You will find data, trends and predictions. Please order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for The Companion Diagnostics (CDx) Market Forecast 2018-2028


Download sample pages

Complete the form below to download your free sample pages for The Companion Diagnostics (CDx) Market Forecast 2018-2028


Latest Pharma news

“Global Human Microbiome Therapeutics market set to grow to $1.6bn” by 2025 says new Visiongain report

The market for microbiome therapeutics is expected to commence around mid-2020 with the launch of new products relating to dermatology and gastrointestinal disorders.

04 December 2019

READ

“Global Next-Generation Biologics market set to grow to $42bn by 2024” says new Visiongain report

Technological developments in the next-generation biologics market will be the result of clinical development of multiple platforms in the next-generation antibody, antibody fragment and ALP sectors.

04 December 2019

READ

“Global Liquid Biopsy market set to grow to $4.9bn by 2024” says new Visiongain report

The main drivers for the growth include technological advancements such as development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

04 December 2019

READ

“Global nucleic acid isolation and purification market is anticipated to reach USD 8.16 Billion by 2030”, says Visiongain

Nucleic acid separation and purification is one of modern science and technology’s most complex and critical accomplishments.

29 November 2019

READ

Categories

Category